Evidence map›Paper›PMID 42365365›Full record

Trial reportJournal of hematology & oncology2026

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Nicholas J Short, Alex Bataller, Courtney D DiNardo, Guillermo Montalban-Bravo, Sa A Wang, Wei Wang, Abhishek Maiti, Daniel Nguyen, Maria C Hachem, Timothy M Bi and 11 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05285813 (A Phase II Study of Vibecotamab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05285813 phase2terminatednot on this map

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2022 to 2026Enrolled51ConditionsAML, MDSArmsVibecotamab, Dexamethasone, Acetaminophen, Diphenhydramine
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nicholas J Short *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA. nshort@mdanderson.org.
Alex Bataller *Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Sa A WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abhishek MaitiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Daniel NguyenDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maria C HachemDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Timothy M BiHematopoietic Biology and Malignancy Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Kelly S ChienDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Maro OhanianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Sanam LoghaviDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omer KarrarDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Pavan BachireddyHematopoietic Biology and Malignancy Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hyunsoo HwangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xuelin HuangDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY · 2003 to 2023
$43.7M
MD Anderson Cancer Center Leukemia SPORE CA100632NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NIH/NCI Cancer Center Support Grant P30 CA016672.
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) with persistent measurable residual disease (MRD) and relapsed/refractory myelodysplastic syndromes (MDS) are low-blast myeloid diseases for which there are few effective therapeutic options. CD123 represents an attractive target in these diseases. Vibecotamab is a bispecific antibody that binds to CD123 on malignant blasts and to CD3 on T-cells, to recognize and eliminate CD123-positive malignant cells.

methodsThis single-center phase II study evaluated the efficacy of vibecotamab in patients AML with detectable MRD (AML-MRD cohort) or with MDS or chronic myelomonocytic leukemia (CMML) after hypomethylating agent failure (MDS/CMML cohort). In cycle 1, patients received vibecotamab IV on day 1 (0.43 µg/kg), day 3 (0.75 µg/kg), day 5 (1.1 µg/kg), and days 8, 15 and 22 (1.7 µg/kg). In subsequent cycles, patients received vibecotamab IV on days 1, 8, 15, and 22 (1.7 µg/kg). The primary outcomes were MRD negativity rate (AML-MRD cohort) and overall response (MDS/CMML cohort).

resultsBetween May 2022 and April 2025, 48 patients were enrolled (21 AML-MRD cohort, 27 MDS/CMML cohort). The median ages of the AML-MRD and the MDS/CMML cohorts were 70 and 76 years, respectively. In the AML-MRD cohort, the median MRD level by flow cytometry was 0.64% (range, 0.1-3.9%), and in the MDS/CMML, the median bone marrow blast percentage was 7% (range, 3-19%). The AML-MRD clearance rate was 19% (4/21; 95% CI 5-42%), and in the MDS/CMML cohort, the overall response rate was 67% (18/27; 95% CI 46-83%). The median overall survival was 13.1 months (95% CI 8.9-NR) for the AML-MRD cohort and 6.5 months (95% CI 4.2-10.3) for the MDS/CMML cohort. The most frequent adverse event was infusion reaction or cytokine relapse syndrome, which occurred in 29 patients (60%) overall, most of which were grade 1-2.

conclusionsVibecotamab was active in low-blast myeloid diseases, although the durability of responses was modest. Additional studies of CD123-targeting bispecific antibodies, alone or in combination, are warranted for these diseases.

trial registrationClinicaltrials.gov (NCT05285813).

Indexed as

Antibodies, BispecificLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesNeoplasm, ResidualAdultAgedAged, 80 and overFemaleHumansInterleukin-3 Receptor alpha SubunitMaleMiddle AgedAntibodies, BispecificInterleukin-3 Receptor alpha SubunitAcute myeloid leukemiaBispecific antibodyChronic myelomonocytic leukemiaClinical trialImmunotherapyMeasurable residual diseaseMyelodysplastic syndromes

Identifiers

PMID42365365
PMCPMC13536830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.